Ardelyx, Inc.
Case Overview
20 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 10/15/2024 |
Status: | Status: Investigating |
Company Name: | Company Name: Ardelyx, Inc. |
Court: | Court: District of Massachusetts |
Case Number: | Case Number: 1:24cv12119 |
Class Period: | Class Period: 10/31/2023 - 07/01/2024 |
Ticker: | Ticker: ARDX |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) securities during the period of October 31, 2023 to July 1, 2024, inclusive (“the Class Period”). Investors have until October 15, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Ardelyx class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that Ardelyx had not reached a firm decision concerning whether or not to apply to include XPHOZAH in Transitional Drug Add-on Payment Adjustment (“TDAPA”), a program to pay for new ESRD-related therapies not yet in the ESRD Prospective Payment System (“ESRD PPS”) bundle , and could not, in fact, decide whether or not to submit such an application to the Centers for Medicare and Medicaid Services (“CMS”) until after defendants first reviewed CMS’s proposed calendar year 2025 ESRD PPS rule, which was only issued on June 27, 2024.
The Ardelyx class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that Ardelyx had not reached a firm decision concerning whether or not to apply to include XPHOZAH in Transitional Drug Add-on Payment Adjustment (“TDAPA”), a program to pay for new ESRD-related therapies not yet in the ESRD Prospective Payment System (“ESRD PPS”) bundle , and could not, in fact, decide whether or not to submit such an application to the Centers for Medicare and Medicaid Services (“CMS”) until after defendants first reviewed CMS’s proposed calendar year 2025 ESRD PPS rule, which was only issued on June 27, 2024.